MRD-guided therapy for CLL balances treatment cessation risks with cumulative toxicity concerns, offering a promising alternative to continuous or fixed-duration therapies. The VISION/HOVON141 trial ...
MRD-guided retreatment with anti-CD20 antibodies may improve survival outcomes in high-risk, relapsed CLL patients by initiating therapy before clinical relapse. The study showed MRD-triggered ...
Researchers sought to determine whether fixed-duration treatment with venetoclax + obinutuzumab/ibrutinib would have similar efficacy to continuous ibrutinib therapy in CLL.
Measurable residual disease-guided ibrutinib-venetoclax therapy achieved undetectable disease in bone marrow in 66.2% of patients with chronic lymphocytic leukemia (CLL) within 2 years compared with ...
MRD quantification allows for improved PFS prediction in both patients who achive PR and CR, which thus supports its application in all responders. In contrast to residual lymphadenopathy, persisting ...
ORLANDO -- A year of combination therapy for previously untreated chronic lymphocytic leukemia (CLL) patients led to similar outcomes compared with indefinite BTK inhibition with ibrutinib (Imbruvica) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results